On this page
- What type 2 diabetes is
- How much standard treatment has changed
- What the cell therapy evidence says
- Where the evidence is actually stronger
- Type 1 and type 2 are different problems
- What would need to be shown
- Risks in this population
- A realistic summary
- Frequently asked questions
- Requesting a medical evaluation
A meta-analysis exists, its title contains the word “possible”, and that word is doing more work than anything else on this page. Type 2 diabetes and stem cell therapy sits in a field where the established treatments have improved dramatically and where the complications — not the glucose number — are what actually matter.
What type 2 diabetes is
Cells stop responding properly to insulin, and the pancreas compensates by producing more. Over years that compensation fails as beta cell function declines, and blood glucose rises.
It is progressive in most people, which is why treatment usually intensifies over time rather than staying static.
The damage is done by sustained high glucose to small and large blood vessels — affecting eyes, kidneys, nerves, heart and circulation. The glucose reading is a marker; the vessels are the disease.
That distinction matters when weighing any treatment: lowering a number is only useful if it prevents what the number predicts.
How much standard treatment has changed
Metformin remains first-line. What has changed is everything after it — GLP-1 receptor agonists and SGLT2 inhibitors reduce cardiovascular and kidney outcomes, not merely glucose, which is a genuinely different order of evidence.
Weight reduction can produce remission in a meaningful proportion of people, particularly earlier in the disease. That is remission, achieved without any cell therapy.
Structured lifestyle intervention, bariatric surgery in appropriate candidates, and management of blood pressure and lipids all have outcome data behind them.
Any cell therapy is entering a field where the competition is strong and getting stronger. That is unusual on this site — for most indications here standard care is limited, which is part of why people look elsewhere. In type 2 diabetes the opposite is true.
What the cell therapy evidence says
A 2024 meta-analysis concluded that MSC therapy can be a possible treatment for diabetes — Meta-analysis shows that mesenchymal stem cell therapy can be a possible treatment for diabetes.
A 2025 systematic review and network meta-analysis assessed interventions to preserve insulin-secreting beta cell function — A systematic review and network meta-analysis of interventions to preserve insulin-secreting beta cell function.
Read the first title again. “Can be a possible treatment” is how researchers write when the direction is encouraging and the case is not made. Marketing summaries reliably drop both qualifiers.
Where the evidence is actually stronger
Not in the diabetes itself, but in two of its complications — which is worth knowing, because it points somewhere more useful.
Diabetic foot ulcers have a prospective randomised controlled trial behind them — Prospective, Randomized, and Controlled Study of a Human Umbilical Cord Mesenchymal Stem Cell Injection for Treating Diabetic Foot Ulcer. See diabetic foot ulcer.
Diabetic kidney disease has a randomised clinical trial — Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial.
A localised problem with a defined endpoint is an easier target than a systemic metabolic disease, and the evidence reflects that. A wound either closes or it does not; a metabolic disease is measured across a dozen shifting variables over decades.
Type 1 and type 2 are different problems
Type 1 is autoimmune destruction of beta cells, usually earlier in life, requiring insulin from diagnosis. Type 2 is insulin resistance with progressive beta cell failure.
A treatment aimed at protecting or replacing beta cells has a clearer rationale in type 1. A treatment aimed at insulin resistance is addressing something quite different.
Clinics that market to “diabetics” without distinguishing the two are not being precise about what they claim to treat, and that imprecision usually runs in one direction — borrowing the clearer rationale from type 1 while selling to the much larger type 2 population.
What would need to be shown
Durable improvement in glucose control, and ideally a reduction in insulin or medication requirement, sustained beyond the months most trials run for.
Then, much harder, a reduction in the complications that matter — cardiovascular events, kidney decline, retinopathy, neuropathy. That requires years and large numbers.
No cell therapy has demonstrated the second, and the drugs it would be competing against have. That is the comparison that matters, and it is rarely the comparison offered.
Risks in this population
People with long-standing diabetes often have cardiovascular disease, kidney impairment and impaired healing, all of which raise the risk of any procedure.
Infection risk is higher, and wound healing at any harvest site is slower — relevant if autologous cells are proposed. There is a further consideration seldom raised: cells harvested from someone with long-standing metabolic disease may not behave like cells from a healthy donor, which is an argument for donor material if this is being pursued at all — see autologous versus allogeneic.
The specific risk is the familiar one: reducing established medication in favour of something unproven, while the vessel damage continues quietly — see adverse events.
A realistic summary
Early evidence, honestly described by its own authors as possible rather than established, against a background of standard treatments that now demonstrably reduce the outcomes patients care about.
Where there is a specific complication — a non-healing ulcer, declining kidney function — the evidence is narrower and better, and that is where a conversation is most defensible.
See the main treatment page and what the evidence levels mean.
Two related pages cover its complications: nerve damage and neuropathy, which has a randomised phase 2a trial behind it, and metabolic syndrome, which has none at all.
Frequently asked questions
Can stem cells reverse type 2 diabetes?
No trial has shown that. A meta-analysis describes a possible treatment, which is how researchers write when the case is not yet made.
Could I stop my medication?
Nothing in the evidence supports that, and modern drugs reduce cardiovascular and kidney outcomes rather than just glucose. That is a high bar to replace.
Is anything better evidenced?
Yes — in the complications. Diabetic foot ulcers and diabetic kidney disease each have a randomised trial, which the diabetes itself does not.
Does type 1 or type 2 matter?
Substantially. Type 1 is autoimmune beta cell destruction; type 2 is insulin resistance with progressive beta cell failure. The rationale differs.
Can diabetes go into remission?
Yes, in a meaningful proportion of people through substantial weight reduction, particularly in the first few years after diagnosis. That is achieved without any cell therapy, and it is the option worth exhausting first.
Are there extra risks for me?
Often. Cardiovascular disease, kidney impairment and slower healing are common in long-standing diabetes and raise the risk of any procedure.
Requesting a medical evaluation
Nothing on this page establishes whether any treatment is appropriate for you. That needs your history, your imaging and your current medications read by a clinician. If you would like that review, send your records and we will tell you honestly whether there is anything worth discussing — including when the answer is no.
This page is general information, not medical advice, and does not create a doctor–patient relationship. Regenerative treatments discussed here are in most cases investigational. Discuss any treatment with a clinician who knows your history.